COVID-19
MONDO:0100096A disease caused by infection with severe acute respiratory syndrome coronavirus 2.
Also known as: 2019 novel coronavirus infection, 2019-nCoV infection, coronavirus disease 2019, severe acute respiratory syndrome coronavirus 2 infectious disease, 2019 novel coronavirus, 2019-nCoV, SARS-CoV-2, SARS-coronavirus 2
914 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Sanofi's COVID vaccine trial ends early – what we know
⭐️ VACCINE ⭐️ TerminatedThis Phase 3 study tested two Sanofi COVID-19 vaccines (one targeting the original virus, another targeting two variants) in about 24,000 adults. The goal was to see if they could prevent COVID-19 safely. The trial was terminated early, so final results are limited, but the data …
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:00 UTC
-
COVID vaccine trial for babies halted early – Here's what we know
⭐️ VACCINE ⭐️ TerminatedThis study looked at whether the mRNA-1273.214 COVID-19 vaccine is safe and works in infants as young as 12 weeks to under 6 months old. It was a small, early-stage trial that was stopped before completion. The main goal was to check for side effects like fever, fussiness, and in…
Phase: PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:00 UTC
-
Sanofi mRNA vaccine trial ends early – what we know
⭐️ VACCINE ⭐️ TerminatedThis study tested Sanofi's experimental mRNA vaccine against COVID-19 in 182 healthy adults aged 18 and older. The main goals were to check safety and measure the body's immune response. The trial was terminated early, so full results are not available.
Phase: PHASE1, PHASE2 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 26, 2026 15:56 UTC
-
Malaria drug combo shows promise against COVID-19 in early trial
Disease control TerminatedThis phase 2 trial tests whether a combination of atovaquone (an anti-malarial) and azithromycin (an antibiotic) can clear the COVID-19 virus in infected adults. The study enrolls people at high risk for complications, such as those with moderate to severe illness. Participants r…
Phase: PHASE2 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Placenta cells tested as COVID fighter – but trial stopped early
Disease control TerminatedThis early-phase trial tested a new therapy called CYNK-001, which uses natural killer cells from the placenta to fight COVID-19. It enrolled only 7 adults with moderate COVID-19. The study was terminated early, so we have limited information on safety and effectiveness.
Phase: PHASE1, PHASE2 • Sponsor: Celularity Incorporated • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Experimental drug aims to help COVID survivors breathe easier
Disease control TerminatedThis study tested a drug called deupirfenidone (LYT-100) in 185 adults who had breathing problems after a serious COVID-19 infection. Participants took either the drug or a placebo for several weeks to see if it improved their ability to walk. The trial was stopped early, so the …
Phase: PHASE2 • Sponsor: PureTech • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Can an extra shot boost COVID protection in autoimmune patients?
Disease control TerminatedThis study tests whether an additional dose of a COVID-19 vaccine can improve immune protection in adults and children with autoimmune diseases like rheumatoid arthritis, lupus, multiple sclerosis, and others who are taking immunosuppressive medications. Participants who had a we…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
COVID-19 drug trial halted early: only 16 patients enrolled
Disease control TerminatedThis study tested an experimental drug called APX-115 in hospitalized patients with mild to moderate COVID-19. The goal was to see if it was safe and could help people recover faster. However, the trial was stopped early and only 16 people took part, so we don't have enough infor…
Phase: PHASE2 • Sponsor: Aptabio Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Can a smaller dose of arthritis drug tame COVID-19 lung inflammation?
Disease control TerminatedThis study tested whether a low dose of tocilizumab, a drug used for arthritis, could help hospitalized COVID-19 patients with lung inflammation who were not on a breathing machine. The goal was to see if it sped up recovery and reduced deaths. The trial was stopped early, but re…
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental drug INB03 tested to stop COVID-19 lung decline – trial halted early
Disease control TerminatedThis study tested a drug called INB03 in 79 high-risk COVID-19 patients to see if it could prevent their breathing from getting worse. Participants received two weekly injections of either INB03 or a placebo. The trial was terminated early, so we do not have clear results on whet…
Phase: PHASE2, PHASE3 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Plasma from recovered patients tested against COVID-19 – trial ends early
Disease control TerminatedThis study tested whether giving plasma (the liquid part of blood) from people who recovered from COVID-19 could help hospitalized patients with moderate to severe COVID-19. The plasma contains antibodies that might fight the virus. The trial planned to enroll many patients but w…
Phase: PHASE3 • Sponsor: South African National Blood Service • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Heart drug tested to fight COVID-19 complications
Disease control TerminatedThis study tested a drug called CardiolRx in 90 hospitalized COVID-19 patients who also had heart disease or risk factors like diabetes or high blood pressure. The goal was to see if the drug could lower the chance of death, needing intensive care, or having heart problems. The t…
Phase: PHASE2, PHASE3 • Sponsor: Cardiol Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Cancer drug tested against COVID-19 in small trial
Disease control TerminatedThis study tested whether imatinib, a drug used for certain cancers, could help hospitalized adults with COVID-19. Participants received either imatinib or a placebo alongside standard care. The trial was stopped early and only included 21 people, so no firm conclusions can be dr…
Phase: PHASE3 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could a simple gas stop COVID-19 from getting worse?
Disease control TerminatedThis study tested whether breathing in nitric oxide gas could keep mild-to-moderate COVID-19 from becoming severe. Researchers enrolled 62 hospitalized adults who were breathing on their own. The goal was to see if the gas reduced the need for a breathing tube. The trial was stop…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental drug auxora tested in critical COVID-19 lung patients
Disease control TerminatedThis small Phase 2 trial tested an experimental drug called Auxora in 10 patients with critical COVID-19 pneumonia who were on ventilators. The goal was to see how the drug affected immune cells in the lungs and to check its safety. The study was terminated early, so results are …
Phase: PHASE2 • Sponsor: CalciMedica, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Could a nausea drug help fight COVID-19? early trial cut short
Disease control TerminatedThis phase 2 trial tested whether adding aprepitant, a drug usually used for nausea, to standard care could help hospitalized COVID-19 patients recover faster. The study planned to enroll adults recently admitted to the hospital with COVID-19 and signs of lung involvement. Howeve…
Phase: PHASE2 • Sponsor: Heron Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug fails to show benefit in severe COVID-19 pneumonia trial
Disease control TerminatedThis study tested whether adding reparixin to standard care could prevent death or the need for a breathing machine in 414 hospitalized adults with COVID-19 or other pneumonia. The trial was stopped early. Researchers compared reparixin to a placebo to see if it reduced severe ou…
Phase: PHASE3 • Sponsor: Dompé Farmaceutici S.p.A • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Can an arthritis drug tame severe COVID-19?
Disease control TerminatedThis study tested the drug tocilizumab (Actemra) in hospitalized adults with severe COVID-19 and signs of inflammation. Participants received either the drug or a placebo, with the goal of improving clinical status by day 28. The trial was terminated early after enrolling only 20…
Phase: PHASE3 • Sponsor: Queen's Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Hydroxychloroquine COVID trial fizzles: only 17 patients enrolled
Disease control TerminatedThis study tested whether hydroxychloroquine (a malaria drug) could help hospitalized COVID-19 patients recover faster. It planned to enroll 350 people but was stopped early with just 17 participants. Because it ended so early, we cannot say whether the drug works or is safe for …
Phase: PHASE3 • Sponsor: Queen's Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
COVID-19 drug trial halted early: what happened with ensovibep?
Disease control TerminatedThis study tested a single dose of ensovibep, a lab-made protein, in 407 adults with mild COVID-19 symptoms. The goal was to see if it could lower the amount of virus in the body and reduce hospitalizations. The trial was stopped early, so we don't have complete answers on how we…
Phase: PHASE2, PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
COVID-19 drug trial halted after just 4 patients
Disease control TerminatedThis study tested whether a medicine called emetine could help adults aged 30 and older recover from COVID-19. Participants took emetine or a placebo daily for 10 days. The trial was stopped early after only 4 people enrolled, so we don't have enough information to know if emetin…
Phase: PHASE2, PHASE3 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Cancer Patients' COVID-19 trial halted after just 4 volunteers
Disease control TerminatedThis early-phase study aimed to see if combining two immune-stimulating drugs (rintatolimod and interferon alpha-2b) could help cancer patients fight off COVID-19. Only 4 people took part before the study was stopped early. The main goals were to check safety and measure how the …
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental drug aims to keep viral pneumonia patients out of hospital
Disease control TerminatedThis Phase 2 trial tested the drug silmitasertib (CX-4945) plus standard care in adults with pneumonia caused by COVID-19 or influenza. The goal was to see if the drug could reduce the need for hospitalization or prevent death. The study planned to enroll 120 people but was termi…
Phase: PHASE2 • Sponsor: Senhwa Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
COVID drug trial for kids halted early
Disease control TerminatedThis study tested the drug baricitinib in children aged 1 to 18 who were hospitalized with COVID-19 and needed extra oxygen. The goal was to see if the drug was safe and how it worked in kids. Only 6 children took part before the study was stopped early.
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Experimental COVID-19 drug fails to prevent respiratory failure in High-Risk patients
Disease control TerminatedThis study tested an experimental drug called ABX464 in 509 high-risk COVID-19 patients aged 65 and older, or those 18+ with risk factors like obesity or diabetes. The goal was to see if the drug could reduce inflammation and prevent the need for high-flow oxygen or a breathing m…
Phase: PHASE2, PHASE3 • Sponsor: Abivax S.A. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
COVID pill trial halted early: what happened?
Disease control TerminatedThis study tested an oral antiviral drug called ensitrelvir in hospitalized COVID-19 patients. The goal was to see if it could help them recover faster. However, the trial was stopped early, so we have limited information on whether it works.
Phase: PHASE3 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
COVID-19 drug trial halted: LAU-7b studied in hospitalized patients
Disease control TerminatedThis study tested an experimental drug called LAU-7b in adults hospitalized with COVID-19 who had health issues like diabetes that put them at higher risk for complications. The goal was to see if LAU-7b could prevent respiratory failure or the need for a breathing machine. The t…
Phase: PHASE2, PHASE3 • Sponsor: Laurent Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
COVID-19 antibody drug trial halted early — little data to show
Disease control TerminatedThis early-stage study tested a new antibody drug (REGN14256) alone or with imdevimab in 25 adults with mild COVID-19 and no risk factors for severe illness. The goal was to check safety and whether the drug could lower virus levels. However, the trial was terminated early, so we…
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
COVID antibody drug trial halted: hope for severe cases unfulfilled
Disease control TerminatedThis study tested a lab-made antibody called SCTA01 in adults hospitalized with severe COVID-19. The goal was to see if it could help them recover faster. The trial was stopped early, so we don't have clear results on its effectiveness.
Phase: PHASE2, PHASE3 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
COVID antibody study for vulnerable kids halted early
Disease control TerminatedThis study tested a single injection of two lab-made antibodies (casirivimab and imdevimab) in children under 12 who are at high risk for severe COVID-19. The goal was to see how the drug behaves in the body, if it is safe, and if it triggers an immune response. Only 7 children t…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
COVID antibody drug tested in kids – but study stopped early
Disease control TerminatedThis study tested a single dose of casirivimab+imdevimab (REGN-COV2) in children hospitalized with COVID-19. The goal was to see how the drug behaves in the body and whether it is safe. However, the study was terminated early and only enrolled 2 participants, so we have very litt…
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Stem cell infusions aim to tame COVID-19 inflammation
Disease control TerminatedThis study tested whether infusions of stem cells from donated fat tissue could help people with COVID-19. The trial planned to enroll 48 adults and compare four doses of stem cells against a placebo. The goal was to see if the treatment could reduce inflammation and improve oxyg…
Phase: PHASE2 • Sponsor: Hope Biosciences Research Foundation • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Hydroxychloroquine trial for COVID-19 fizzles out
Disease control TerminatedThis early-phase study tested whether hydroxychloroquine, a drug used for malaria and autoimmune diseases, could reduce the amount of virus in adults with mild COVID-19 not needing oxygen. Only 8 people took part before the trial was stopped early. The study was too small to draw…
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope against deadly molds? early trial cut short
Disease control TerminatedThis study tested a drug called fosmanogepix in 21 adults with invasive mold infections (like Aspergillus or rare molds) who had few other options. The trial was stopped early, so we have limited data on how well it works or its safety.
Phase: PHASE2 • Sponsor: Basilea Pharmaceutica • Aim: Disease control
Last updated Jun 26, 2026 17:54 UTC
-
Kidney transplant patients get extra COVID shot in new trial
Disease control TerminatedThis phase 3 trial tested whether a dose of the Janssen COVID-19 vaccine could boost immunity in kidney transplant recipients who had already received two or three mRNA vaccine doses. The study enrolled 468 participants and also looked at reducing immunosuppression medication. Ho…
Phase: PHASE3 • Sponsor: Mark Stegall • Aim: Disease control
Last updated Jun 26, 2026 17:26 UTC
-
Nasal spray aims to fight COVID-19, but trial halted early
Disease control TerminatedThis study tested a nasal spray called AD17002 in 180 adults with mild to moderate COVID-19. Participants received either a low dose, high dose, or placebo spray alongside standard care. The goal was to see if the spray speeds up recovery and improves symptoms. However, the trial…
Phase: PHASE2, PHASE3 • Sponsor: Advagene Biopharma Co. Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:12 UTC
-
Stem cell shot for COVID-19 fizzles in small trial
Disease control TerminatedThis study tested whether a single infusion of stem cells from umbilical cord tissue (ProTrans®) could help hospitalized adults with severe COVID-19 avoid ventilators or death. The trial was stopped early after enrolling only 19 people, so we cannot draw firm conclusions. Both th…
Phase: PHASE2 • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 26, 2026 15:19 UTC
-
Rapid COVID test studied for emergency triage
Diagnosis TerminatedThis study looked at using a fast, point-of-care COVID-19 test to help doctors quickly decide how to treat patients with serious heart or breathing problems. It involved 66 adults who already tested positive for COVID-19. The goal was to find the best way to collect samples (nose…
Sponsor: Ottawa Heart Institute Research Corporation • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Fingerprint sweat may reveal COVID-19 infection
Diagnosis TerminatedThis study explored whether analyzing sweat from fingerprints using a special camera could quickly detect COVID-19. Researchers enrolled 66 adults who had tested positive or negative for COVID-19 within the past week. Participants provided a fingerprint sweat sample and a blood s…
Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Jun 27, 2026 12:25 UTC
-
Can a One-Minute chair test predict COVID-19 hospital needs?
Diagnosis TerminatedThis study tested whether a one-minute sit-to-stand test could help emergency doctors decide if COVID-19 patients need hospital care. The test measures oxygen levels and breathing effort during repeated standing from a chair. The trial aimed to reduce unnecessary hospital stays b…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Diagnosis
Last updated Jun 27, 2026 08:13 UTC
-
Could a simple gas shield healthcare workers from COVID-19?
Prevention TerminatedThis study tested whether breathing in nitric oxide gas could prevent healthcare workers from catching COVID-19. The plan was to enroll 470 workers, but the trial was stopped early with only 24 participants. Workers in the treatment group inhaled the gas at the start and end of e…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Prevention
Last updated Jun 27, 2026 11:04 UTC
-
Antibody shield for the vulnerable: COVID-19 prevention trial in immunocompromised
Prevention TerminatedThis study tested whether a combination of antibodies (casirivimab+imdevimab) could prevent COVID-19 in people with weakened immune systems, such as transplant recipients or cancer patients. Participants received either the antibodies or a placebo as a shot under the skin. The tr…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Prevention
Last updated Jun 27, 2026 07:55 UTC
-
Nasal spray could be new weapon against COVID-19
Prevention TerminatedThis study tested whether a nitric oxide nasal spray could prevent COVID-19 in people at risk of exposure. About 1,400 adults used the spray or a placebo for 28 days. The trial was terminated early, so final results are not available.
Phase: PHASE3 • Sponsor: Sanotize Research and Development corp. • Aim: Prevention
Last updated Jun 27, 2026 07:51 UTC
-
Mental health sessions may boost vaccine uptake in latinx communities
Prevention TerminatedThis study tested whether adding vaccine discussions to routine behavioral health visits could reduce hesitancy and increase COVID-19 and flu shots among Latinx adults with mental illness. Clinicians used motivational interviewing and could offer a warm handoff to a nurse for vac…
Phase: NA • Sponsor: Boston College • Aim: Prevention
Last updated Jun 26, 2026 17:00 UTC
-
HIV drug fails to prove COVID-19 prevention in abandoned trial
Prevention TerminatedThis study tested whether a daily pill used for HIV (TAF/FTC) could prevent COVID-19 in healthcare workers at high risk of exposure. Over 1,300 workers were randomly assigned to get the drug or a placebo for 12 weeks. The trial was stopped early, so it's unclear if the drug had a…
Phase: PHASE3 • Sponsor: Hospital Italiano de Buenos Aires • Aim: Prevention
Last updated Jun 26, 2026 14:58 UTC
-
Mindfulness app for anxiety in underserved groups fizzles out early
Symptom relief TerminatedThis study tested a smartphone app that teaches mindfulness meditation to help Black and Latino adults with anxiety during the COVID-19 pandemic. About 400 participants were assigned to one of two mindfulness programs or a waitlist. The trial was terminated early, so we don't hav…
Phase: NA • Sponsor: University of North Carolina, Chapel Hill • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Salt water gargle study for COVID-19 fizzles out early
Symptom relief TerminatedThis study tested whether rinsing the nose and gargling with salt water could help people with suspected or confirmed COVID-19 feel better faster. Only 16 adults in the UK took part before the study was stopped early. The goal was to see if this simple home remedy could reduce ho…
Phase: NA • Sponsor: University of Edinburgh • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
Ancient herbal remedy put to the test against COVID-19
Symptom relief TerminatedThis small pilot study tested whether a traditional Chinese medicine called Xuanfei Baidu granules is safe and acceptable for people with mild to moderate COVID-19. Only 10 adults were enrolled before the study was stopped early. The main goal was to see how many people would agr…
Phase: PHASE2 • Sponsor: Darcy Spicer • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Calm app tested on stressed doctors – but study cut short
Symptom relief TerminatedThis study looked at whether using the Calm meditation app could help medical residents and fellows at Banner University Medical Center Phoenix feel less stressed, anxious, or burned out during the COVID-19 pandemic. Only 7 people signed up, and the study was stopped early, so we…
Phase: NA • Sponsor: University of Arizona • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Long COVID rehab study halted early – what we know
Symptom relief TerminatedThis study looked at whether a supervised exercise and pulmonary rehabilitation program could help people with Long COVID feel better and move more easily. Researchers measured changes in aerobic capacity, fatigue, and quality of life in 21 adults who had COVID at least 12 weeks …
Phase: NA • Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
COVID-19 vaccine safety checked in cancer immunotherapy patients
Knowledge-focused TerminatedThis study aimed to see if COVID-19 vaccines cause more side effects in cancer patients receiving immunotherapy. Researchers planned to track 125 patients from several hospitals in France, recording any local or systemic side effects. The study was terminated early, so the full r…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Scientists collect samples from COVID-19 patients to unlock virus secrets
Knowledge-focused TerminatedThis study collected blood, urine, stool, and respiratory samples from 615 COVID-19 patients and caregivers at Bordeaux University Hospital. The goal was to build a biobank for research on the virus and disease. The study was terminated early, but the samples may still help scien…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
COVID-19 may harm the brain in ways scans Can't see
Knowledge-focused TerminatedThis study looked for hidden brain damage in 38 hospitalized COVID-19 patients. Instead of using standard MRI scans, researchers used electrical tests to check how well the brainstem was working. The goal was to find subtle nervous system problems that might not show up on regula…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Web tool aims to ease tough COVID conversations
Knowledge-focused TerminatedThis study tested a web-based guide to help people have conversations about COVID-19. It enrolled 30 adults who spoke English or Spanish. The guide offered virtual conversations tailored to different concerns. The study was terminated early, so results are limited.
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
New ICU cockpit software aims to predict brain complications before they happen
Knowledge-focused TerminatedThis study tested a software platform called ICU Cockpit that collects and displays vital signs and other data from brain-injury patients in the intensive care unit. The goal was to help doctors make faster, better decisions and to predict complications like strokes or unstable c…
Phase: NA • Sponsor: Emanuela Keller • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
AI analyzes 100,000 COVID-19 cases to predict who gets worst outcomes
Knowledge-focused TerminatedThis study used artificial intelligence to analyze electronic health records from 100,000 COVID-19 patients across multiple hospitals. The goal was to identify factors that predict whether a patient would be hospitalized, need ICU care, or die. The study was terminated early, so …
Sponsor: Savana Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Rouen hospital checks accuracy of COVID-19 antibody tests
Knowledge-focused TerminatedThis study aimed to check how accurate several COVID-19 antibody tests are. Researchers used blood samples from 101 adults, including some taken before the pandemic and some from people with other infections. The goal was to see which tests best detect past COVID-19 infection.
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Smart vest monitors COVID patients
Knowledge-focused TerminatedThis study tested a special vest that tracks health data like heart rate and breathing in people hospitalized with COVID-19. The goal was to see if the vest could help doctors spot worsening symptoms early. Only 15 adults took part before the study ended early.
Sponsor: Nanowear Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Arthritis drugs and COVID: study probes immune response
Knowledge-focused TerminatedThis study looked at how immunosuppressive medications used for rheumatoid arthritis and spondyloarthritis affect the body's ability to fight COVID-19. Researchers measured viral load and immune responses in 150 patients and their infected family members. The goal was to understa…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
New brain scanner peers into COVID's neurological mysteries
Knowledge-focused TerminatedThis pilot study tested a new brain PET-MR scanner to see if it can capture clear images of brain metabolism and blood flow in people who had COVID-19 and those who did not. Only 3 participants were enrolled before the study ended early. The goal was to develop an imaging protoco…
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Sticker shock: simple reminder may cut unnecessary IV antibiotic use
Knowledge-focused TerminatedThis study tested whether placing a reminder sticker on the charts of adult hospital patients receiving IV fluoroquinolone antibiotics would encourage doctors to switch them to oral pills sooner. The trial involved 168 patients at a single hospital in Thailand. Unfortunately, the…
Phase: NA • Sponsor: Mahidol University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Rural pharmacists get virtual coaching to tackle vaccine hesitancy
Knowledge-focused TerminatedThis study looked at whether virtual coaching helps rural pharmacists better counsel patients who are hesitant about COVID-19 vaccines. Sixteen pharmacies took part, first receiving standard training and then adding one-on-one video coaching. The main goal was to see if coaching …
Phase: NA • Sponsor: University of North Carolina, Chapel Hill • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Cancer Patients' COVID risk explored in terminated study
Knowledge-focused TerminatedThis study aimed to understand how COVID-19 affects people with cancer, especially those receiving treatment. Researchers planned to measure how many cancer patients had COVID-19 without symptoms and how their immune systems responded. The study was terminated early, so results a…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
COVID-19's hidden heart damage: study aims to find clues
Knowledge-focused TerminatedThis study followed 80 adults who recovered from COVID-19 to check for heart problems. Participants had heart exams and blood tests one month and one year after recovery. The goal was to understand how often and what kind of heart issues occur after COVID-19, so doctors can bette…
Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Updated pfizer Shot's Real-World power under review
Knowledge-focused TerminatedThis study aimed to measure how well the 2024-2025 Pfizer COVID-19 vaccine prevents symptomatic infection in people visiting CVS MinuteClinics. Researchers planned to compare vaccinated and unvaccinated patients across age groups and variant periods. However, the study was termin…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Smart band tracks COVID-19 breathing trouble
Knowledge-focused TerminatedThis study tested a special band called AirGo to monitor breathing patterns in hospitalized COVID-19 patients with respiratory failure. The goal was to see if the band could detect early signs of worsening breathing, helping doctors decide when to use a breathing tube. The study …
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Early safety test of iCP-NI drug halted before completion
Knowledge-focused TerminatedThis early-phase study tested the safety and tolerability of an experimental drug called iCP-NI in 24 healthy adults. Participants received either the drug or a placebo by intravenous infusion. The trial was terminated, so no conclusions about effectiveness can be drawn.
Phase: PHASE1 • Sponsor: Cellivery Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 26, 2026 19:00 UTC
-
COVID-19 vaccine response under scrutiny in autoimmune patients
Knowledge-focused TerminatedThis study looked at how well the COVID-19 vaccine triggers an immune response in people with autoimmune or inflammatory diseases who take immunosuppressants or biologics. Researchers took blood samples before vaccination and at several points after to measure antibodies and T-ce…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:24 UTC
-
COVID-19's hidden toll on the retina: eye scans reveal damage
Knowledge-focused TerminatedThis study aimed to collect eye scans from people who had COVID-19 to see if the virus caused damage to the retina, the light-sensitive tissue at the back of the eye. Researchers planned to compare severe and mild COVID-19 cases, but the study was stopped early and only enrolled …
Sponsor: Centre Hospitalier Intercommunal Creteil • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:34 UTC